Steward Partners Investment Advisory LLC Reduces Position in Pro-Dex, Inc. (NASDAQ:PDEX)

Posted by MarketBeat News on Aug 3rd, 2022

Steward Partners Investment Advisory LLC lessened its holdings in shares of Pro-Dex, Inc. (NASDAQ:PDEX – Get Rating) by 31.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,388 shares of the medical instruments supplier’s stock after selling 2,428 shares during the period. Steward Partners Investment Advisory LLC owned 0.15% of Pro-Dex worth $89,000 at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PDEX. StockNews.com initiated coverage on shares of Pro-Dex in a research note on Monday. They set a “hold” rating for the company. Ascendiant Capital Markets dropped their price target on shares of Pro-Dex to $30.00 and set a “na” rating for the company in a research note on Monday, May 16th.

Pro-Dex Stock Performance

Shares of PDEX stock opened at $15.40 on Wednesday. The firm’s 50 day moving average price is $15.74 and its 200-day moving average price is $17.09. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.10 and a current ratio of 3.64. Pro-Dex, Inc. has a one year low of $12.40 and a one year high of $32.00. The firm has a market cap of $55.75 million, a P/E ratio of 17.70 and a beta of 1.01.

Pro-Dex (NASDAQ:PDEX – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $0.12 EPS for the quarter. Pro-Dex had a net margin of 8.50% and a return on equity of 15.41%. The firm had revenue of $9.27 million for the quarter.

Pro-Dex Company Profile

(Get Rating)

Pro-Dex, Inc designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.